Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.

Jennifer A HollywoodAneta J PrzepiorskiRandall F D'SouzaSreevalsan SreebhavanErnst J WolvetangPatrick T HarrisonAlan J DavidsonTeresa M Holm

Published in: Journal of the American Society of Nephrology : JASN (2020)

These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis.

Keyphrases

induced pluripotent stem cells
combination therapy
cell proliferation
endothelial cells
emergency department
human health
smoking cessation